[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614809":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":259,"collaborators":25,"id":261,"slug":262,"hasResults":263,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":25,"eligibilityCriteria":267,"healthyVolunteers":263,"sex":268,"minAge":269,"maxAge":25,"enrollmentInfo":270,"targetDuration":25,"studyType":273,"phases":274,"briefSummary":276,"conditions":277,"keywords":25,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":293},{"fullName":5,"class":6},"argenx","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Efgartigimod IV + Empasiprubart IV","EXPERIMENTAL","Participants receive efgartigimod IV in part A, B and C and empasiprubart IV in part B",[13,14],"Biological: Efgartigimod IV","Biological: Empasiprubart IV",{"label":16,"type":10,"description":17,"interventionNames":18},"Efgartigimod IV (part A + C)","Participants not eligible for part B, receiving efgartigimod IV in part A and C",[13],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"BIOLOGICAL","Efgartigimod IV","Intravenous infusion of efgartigimod",[16,9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Empasiprubart IV","Intravenous infusion of empasiprubart",[9],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Sabine Coppieters, MD","CONTACT","857-350-4834","clinicaltrials@argenx.com",[37,56,71,85,96,111,121,136,151,166,180,196,211,227,242],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Profound Research LLC - Carlsbad","RECRUITING","Carlsbad","California","92011","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-117.35059,33.15809,{"lat":49,"lon":48},[52],{"name":53,"role":33,"phone":54,"phoneExt":25,"email":55},"Gregory Sahagian, MD","760-732-0557","greg@profoundresearch.com",{"facility":57,"status":39,"city":58,"state":59,"zip":60,"country":43,"countryCode":44,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Visionary Investigators Network","Miami","Florida","33176",{"type":46,"coordinates":62},[63,64],-80.19366,25.77427,{"lat":64,"lon":63},[67],{"name":68,"role":33,"phone":69,"phoneExt":25,"email":70},"Andrew Lerman, MD","786-655-8010","alerman@fcneurology.net",{"facility":72,"status":39,"city":73,"state":59,"zip":74,"country":43,"countryCode":44,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"University of South Florida","Tampa","33620",{"type":46,"coordinates":76},[77,78],-82.45843,27.94752,{"lat":78,"lon":77},[81],{"name":82,"role":33,"phone":83,"phoneExt":25,"email":84},"Tuan Vu, MD","813-974-9413","tvu6@usf.edu",{"facility":86,"status":87,"city":88,"state":89,"zip":90,"country":43,"countryCode":44,"cosmosGeoPoint":91,"geoPoint":95,"contacts":25},"Henry Ford Health Systems","ACTIVE_NOT_RECRUITING","Detroit","Michigan","48202-2608",{"type":46,"coordinates":92},[93,94],-83.04575,42.33143,{"lat":94,"lon":93},{"facility":97,"status":39,"city":98,"state":99,"zip":100,"country":43,"countryCode":44,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Dent Neurologic Institute - Amherst","Amherst","New York","14226",{"type":46,"coordinates":102},[103,104],-78.79976,42.97839,{"lat":104,"lon":103},[107],{"name":108,"role":33,"phone":109,"phoneExt":25,"email":110},"Luisa Rojas Estupinan, MD","716-250-2000","aemborsky@dentinstitute.com",{"facility":112,"status":87,"city":113,"state":114,"zip":115,"country":43,"countryCode":44,"cosmosGeoPoint":116,"geoPoint":120,"contacts":25},"Duke Early Phase Clinical Research Unit - PPDS","Durham","North Carolina","27710-0001",{"type":46,"coordinates":117},[118,119],-78.89862,35.99403,{"lat":119,"lon":118},{"facility":122,"status":39,"city":123,"state":124,"zip":125,"country":43,"countryCode":44,"cosmosGeoPoint":126,"geoPoint":130,"contacts":131},"Ohio State Martha Morehouse Outpatient Care","Columbus","Ohio","43221-3502",{"type":46,"coordinates":127},[128,129],-82.99879,39.96118,{"lat":129,"lon":128},[132],{"name":133,"role":33,"phone":134,"phoneExt":25,"email":135},"Miriam Freimer, MD","614-293-4969","Miriam.Freimer@osumc.edu",{"facility":137,"status":39,"city":138,"state":139,"zip":140,"country":43,"countryCode":44,"cosmosGeoPoint":141,"geoPoint":145,"contacts":146},"Erlanger Health System","Chattanooga","Tennessee","37403",{"type":46,"coordinates":142},[143,144],-85.30968,35.04563,{"lat":144,"lon":143},[147],{"name":148,"role":33,"phone":149,"phoneExt":25,"email":150},"Joshua Alpers, MD","423-778-3900","joshua.alpers@erlanger.org",{"facility":152,"status":39,"city":153,"state":154,"zip":155,"country":43,"countryCode":44,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"National Neuromuscular Research Institute","Austin","Texas","78756",{"type":46,"coordinates":157},[158,159],-97.74306,30.26715,{"lat":159,"lon":158},[162],{"name":163,"role":33,"phone":164,"phoneExt":25,"email":165},"Yessar Hussain, MD","512-920-0140","marisol@austinneuromuscle.com",{"facility":167,"status":39,"city":168,"state":154,"zip":169,"country":43,"countryCode":44,"cosmosGeoPoint":170,"geoPoint":174,"contacts":175},"University of Texas- San Antonio - Health Science Center - PPDS","San Antonio","78229",{"type":46,"coordinates":171},[172,173],-98.49363,29.42412,{"lat":173,"lon":172},[176],{"name":177,"role":33,"phone":178,"phoneExt":25,"email":179},"Ratna Bhavaraju-Sanka, MD","210-567-8229","BhavarajuSan@uthscsa.edu",{"facility":181,"status":39,"city":182,"state":25,"zip":183,"country":184,"countryCode":185,"cosmosGeoPoint":186,"geoPoint":190,"contacts":191},"UZ Leuven - PPDS","Leuven","3000","Belgium","BE",{"type":46,"coordinates":187},[188,189],4.70093,50.87959,{"lat":189,"lon":188},[192],{"name":193,"role":33,"phone":194,"phoneExt":25,"email":195},"Kristl Claeys, MD","+3216344278","kristl.claeys@uzleuven.be",{"facility":197,"status":39,"city":198,"state":199,"zip":200,"country":201,"countryCode":202,"cosmosGeoPoint":203,"geoPoint":207,"contacts":208},"ASST Papa Giovanni XXIII - Ospedale Papa Giovanni XXIII","Bergamo","Lombardy","24127","Italy","IT",{"type":46,"coordinates":204},[205,206],9.66721,45.69601,{"lat":206,"lon":205},[209],{"name":210,"role":33,"phone":34,"phoneExt":25,"email":35},"Giorgia Camera, MD",{"facility":212,"status":39,"city":213,"state":214,"zip":25,"country":215,"countryCode":216,"cosmosGeoPoint":217,"geoPoint":221,"contacts":222},"MICS Centrum Medyczne Bydgoszcz","Bydgoszcz","Kuyavian-Pomeranian Voivodeship","Poland","PL",{"type":46,"coordinates":218},[219,220],18.00762,53.1235,{"lat":220,"lon":219},[223],{"name":224,"role":33,"phone":225,"phoneExt":25,"email":226},"Lukasz Rzepiński, MD","+48523401414","lukasz.rzepinski@mics.medicover.com",{"facility":228,"status":39,"city":229,"state":230,"zip":231,"country":215,"countryCode":216,"cosmosGeoPoint":232,"geoPoint":236,"contacts":237},"Centrum Medyczne Neurologia Slaska","Katowice","Silesian Voivodeship","40-689",{"type":46,"coordinates":233},[234,235],19.02173,50.2597,{"lat":235,"lon":234},[238],{"name":239,"role":33,"phone":240,"phoneExt":25,"email":241},"Marek Smilowski, MD","+48500282494","marek.smilowski@neurologiaslaska.pl",{"facility":243,"status":39,"city":244,"state":245,"zip":246,"country":247,"countryCode":248,"cosmosGeoPoint":249,"geoPoint":253,"contacts":254},"Hospital Regional Universitario de Malaga - Hospital General","Málaga","Malaga","29010","Spain","ES",{"type":46,"coordinates":250},[251,252],-4.42034,36.72016,{"lat":252,"lon":251},[255],{"name":256,"role":33,"phone":257,"phoneExt":25,"email":258},"Guillermina Garcia Martin, MD","+34951291135","guille.garcia.eecc@gmail.com",{"type":260,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100614809","phase-2-adapt-forward-1---isa1---a-study-to-evaluate-empasiprubart-iv-as-add-on-therapy-to-efgartigimod-iv-in-participants-with-achr-ab-seropositive-generalized-myasthenia-gravis-with-a-partial-clinical-response-to-efgartigimod-100614809",false,"NCT07284420","ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod","An ISA to Master Protocol ARGX-999-2-MG-2000 for an Exploratory, Phase 2a, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV as Add-On Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod","Inclusion Criteria:\n\n* Is seropositive for anti-acetylcholine receptor antibodies (AChR-Ab)\n* Has confirmed diagnosis of gMG and is Myasthenia Gravis Foundation of America (MGFA) Class II, III, IVa, or IVb\n* Has documented immunization against encapsulated bacterial pathogens (Neisseria meningitidis and Streptococcus pneumoniae) within 5 years of ISA screening or is willing to receive immunization at least 14 days before the first study drug administration\n\nExclusion Criteria:\n\n* Clinical diagnosis of systemic lupus erythematosus (SLE)\n* Any known complement deficiency\n* Current administration of a complement inhibitor or received zilucoplan or eculizumab \\\u003C2 months or ravulizumab \\\u003C6 months before the first study drug administration\n* Patients proven to be refractory to efgartigimod (ie, not achieving a clinically meaningful improvement in total Myasthenia Gravis Activities of Daily Living (MG-ADL) score defined as an improvement of ≥2 points)","ALL","18 Years",{"count":271,"type":272},70,"ESTIMATED","INTERVENTIONAL",[275],"PHASE2","This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.\n\nThe aim of this ISA1 is to evaluate the safety and therapeutic relevance of empasiprubart as add-on therapy to efgartigimod in participants with AChR-Ab seropositive generalized myasthenia gravis.\n\nThe ADAPT Forward master protocol is registered on https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT07294170",[278,279,280,281,282,283],"AChR-Ab Seropositive Generalized Myasthenia Gravis","Myasthenia Gravis","MG","gMG","Generalized Myasthenia Gravis","Generalized Myasthenia Gravis (gMG)","2026-06-11",{"date":286,"type":287},"2026-06-12","ACTUAL",{"date":289,"type":287},"2025-12-19",{"date":291,"type":272},"2028-03-07",{"name":5,"class":6},15]